News
HOTH
--
0.00%
--
GEVO, GLNG, GOEV and TEF among notable premarket gainers
Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a
Seekingalpha · 5d ago
FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%
Hoth Therapeutics' (HOTH) jumps 15% premarket in reaction to the announcement that its Pre-IND meeting requested on Dec. 22 for HT-001 with the FDA has been granted to receive written responses that are
Seekingalpha · 5d ago
FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients
, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting for HT-001 with the U.S. Food and Drug Administration (FDA) Division of Dermatology and Dental Products has been granted to receive...
PR Newswire - PRF · 5d ago
FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA) Division of Dermatology and Dental Products has been granted ...
PR Newswire · 5d ago
BRIEF-Ionic Ventures Llc Reports 9.21% Passive Stake In Hoth Therapeutics
reuters.com · 01/12 11:49
Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer
Hoth Therapeutics (HOTH) announces an agreement with Charles River Laboratories (CRL) to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of rash and skin disorders associated with
Seekingalpha · 01/11 13:17
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with to initiate preclinical studies of , a topical formulation designed for the treatment of patients with rash and skin disorders associ...
PR Newswire - PRF · 01/11 13:02
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
NEW YORK , Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001 , a topical formulation desig...
PR Newswire · 01/11 13:02
Synthetic Biologics, Check-Cap leads healthcare gainers; Bionano Genomics, Mersana Therapeutics among major losers
Gainers: Synthetic Biologics (SYN) +149%, Check-Cap (CHEK) +59%, Jaguar Health (JAGX) +50%, Cyclo Therapeutics CYTH +36%, Zomedica (ZOM) +42%.Losers: Bionano Genomics BNGO -29%, Mersana Therapeutics (MRSN) -23%, Millendo Therapeutics (MLND) -18%, TransEnterix (TRXC) -17%, Hoth Therapeutics HOTH -12%.
Seekingalpha · 01/05 16:05
Hoth Therapeutics slides on private placement of equity priced at-the-market
Hoth Therapeutics (HOTH) has entered into a definitive securities purchase agreement in connection with a private placement to institutional investors.The Company expects to receive gross proceeds of ~$5M, not including any proceeds
Seekingalpha · 01/05 14:21
Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules
, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to institutional investors.  Upon the closing...
PR Newswire - PRF · 01/05 14:00
Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%
Hoth Therapeutics (HOTH) jumps 15% premarket in reaction to the announcement that its has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command for a
Seekingalpha · 01/04 13:16
Hoth Therapeutics Announces Licensing Agreement And Collaboration With U.S. Army Medical Research And Development Command For Treating Multi-Drug Resistant Bacterial Lung Infections
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License
Benzinga · 01/04 13:03
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections
, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command (USAMRDC) f...
PR Newswire - PRF · 01/04 13:01
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections
PR Newswire · 01/04 13:01
ACY, AINC, NOVN and ORIC among midday movers
Gainers: AeroCentury Corp. (ACY) +75%.Bonso Electronics International Inc. (BNSO) +61%.Hoth Therapeutics, Inc. (HOTH) +42%.Intrepid Potash, Inc. (IPI) +37%.Ashford Inc. (AINC) +36%.Bionano Genomics, Inc. (BNGO) +33%.Canaan Inc. (CAN) +31%.Red Lion Hotels
Seekingalpha · 12/31/2020 17:27
Bionano Genomics and Ampio Pharmaceuticals among healthcare gainers; Histogen leads losers
Gainers: Hoth Therapeutics (HOTH) +49%. Bionano Genomics (BNGO) +38%. Clearside Biomedical (CLSD) +17%. Regional Health Properties (RHE) +14%. Ampio Pharmaceuticals (AMPE) +13%.Losers: Histogen (HSTO) -26%. Novan (NOVN) -22%. ORIC Pharmaceuticals (ORIC) -14%.
Seekingalpha · 12/31/2020 16:29
Hoth therapeutics signs production agreement for HT-001, Shares up 75%
Biopharmaceutical company Hoth Therapeutics (HOTH) has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment. The update follows
Seekingalpha · 12/31/2020 13:40
BILI, BNGO among premarket gainers
Ashford (AINC) +75%.PEDEVCO (PED) +62%.SGOCO (SGOC) +49%.Ebang International Holdings (EBON) +33%.Red Lion Hotels RLH +31% on being acquired by Sonesta.Canaan (CAN) +30%.AirNet Technology (ANTE) +25%.Hudson Capital HUSN +24% as FreightHub posts stellar Q3 results.Hoth
Seekingalpha · 12/31/2020 13:22
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment
, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001  with Tergus Pharma for its novel cancer treatment drug,...
PR Newswire - PRF · 12/31/2020 13:01
Webull provides a variety of real-time HOTH stock news. You can receive the latest news about Hoth Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About HOTH
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.
More